Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 6/20 | 0.73 |
| ▸ | OXTR | P30559 | 5/20 | 0.73 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24313533 | 1.00 | AVPR1A (0.73) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL14492869 | 1.00 | AVPR1A (0.73) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL29642177 | 1.00 | AVPR1A (0.73) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL5041466 | 1.00 | AVPR1A (0.73) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL24313476 | 1.00 | AVPR1A (0.73) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL4416107 | 0.92 | AVPR1A (0.79) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL5034150 | 0.92 | AVPR1A (0.79) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL24313450 | 0.92 | AVPR1A (0.79) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL29449382 | 0.92 | AVPR1A (0.79) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL5036670 | 0.92 | AVPR1A (0.79) | AVPR1AOXTRAVPR2FFAR2SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390347-B1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACTIVITY | SERONO LAB (CH) | 2008-05-07 | — | — | EP | claimed |
| EP-3252037-B1 | PROCESS FOR THE PREPARATION OF (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2´-METHYL-1,1´-BIPHENYL-4-YL)CARBONYL)PYRROLIDIN-3-ONE O-METHYLOXIME | ObsEva SA (CH) | 2022-03-09 | — | — | EP | disclosed |
| WO-2021043726-A1 | OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVENTING MISCARRIAGE | ObsEva S.A. (CH) | 2021-03-11 | — | — | WO | disclosed |
| US-20210047266-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2021-02-18 | — | — | US | disclosed |
| US-20200281892-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2020-09-10 | — | — | US | disclosed |
| US-20180215708-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2018-08-02 | — | — | US | disclosed |
| US-20180215708-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2018-08-02 | — | — | US | disclosed |
| US-9962367-B2 | Oral formulations of pyrrolidine derivatives | ObsEva S.A. (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9962367-B2 | Oral formulations of pyrrolidine derivatives | ObsEva S.A. (CH) | 2018-05-08 | — | — | US | disclosed |
| US-20170240508-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170240508-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170065556-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2017-03-09 | — | — | US | disclosed |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2015-06-18 | — | — | US | disclosed |
| EP-1390347-B1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACTIVITY | SERONO LAB (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1829861-A2 | Pyrrolidine ester derivatives active as oxytocin antagonists | Applied Research Systems ARS Holding N.V. (AN) | 2007-09-05 | — | — | EP | disclosed |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-06-07 | — | — | US | disclosed |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-06-07 | — | — | US | disclosed |
| US-7189754-B2 | Pyrrolidine ester derivatives with oxytocin modulating activity | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2007-03-13 | — | — | US | disclosed |
| US-7189754-B2 | Pyrrolidine ester derivatives with oxytocin modulating activity | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240508-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | AVPR1A, OXTR, AVPR2 | AVPR1A 1/4885OXTR 2/4885AVPR2 3/4885 |
| US-20200281892-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | KDM5A, KDM5C, KDM5B | AVPR1A 2299/4885OXTR 76/4885AVPR2 1956/4885 |
| US-20180215708-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | OXTR, AVPR1A, AVPR2 | AVPR1A 2/4885OXTR 1/4885AVPR2 3/4885 |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | OXTR, GPR6, CNR1 | AVPR1A 39/4885OXTR 1/4885AVPR2 67/4885 |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | KDM5A, KDM5C, KDM5B | AVPR1A 2299/4885OXTR 76/4885AVPR2 1956/4885 |
| US-20170065556-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | KDM5A, KDM5C, KDM5B | AVPR1A 2299/4885OXTR 76/4885AVPR2 1956/4885 |
| US-20210047266-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | OXTR, AVPR1A, AVPR2 | AVPR1A 2/4885OXTR 1/4885AVPR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.